Cancer Drug Co. Investors Get First OK On $7M Deal
A New York federal judge preliminarily approved a $7 million deal resolving class action claims alleging Spectrum Pharmaceuticals Inc. overstated its regulatory prospects for winning approval for a cancer treatment....To view the full article, register now.
Already a subscriber? Click here to view full article